Overview

Efficacy, Safety, and Tolerability of a Single Administration of COMP360 in Participants With TRD

Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)
Phase:
Phase 3
Details
Lead Sponsor:
COMPASS Pathways
Treatments:
Psilocybin